TrialThe Lancet. Oncology2018

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Lorenza Rimassa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.